Evidence map›Paper›PMID 31195965›Full record

ArticleBMC microbiology2019

Xenorhabdus khoisanae SB10 produces Lys-rich PAX lipopeptides and a Xenocoumacin in its antimicrobial complex.

J Dreyer, M Rautenbach, E Booysen, A D van Staden, S M Deane, L M T Dicks

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 31 citations in OpenAlex.

  1. Pleiotropic role of PAX cyclolipopeptides in theApplied and environmental microbiology · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Life (Basel, Switzerland) · 2022
    Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

J DreyerDepartment of Microbiology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.
M RautenbachBIOPEP Peptide Group, Department of Biochemistry, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. mra@sun.ac.za.
E BooysenDepartment of Microbiology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.
A D van StadenDepartment of Microbiology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.
S M DeaneDepartment of Microbiology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa.
L M T DicksDepartment of Microbiology, Stellenbosch University, Private Bag X1, Matieland, 7602, South Africa. LMTD@sun.ac.za.ORCID 0000-0002-5157-9046
Stellenbosch University · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundXenorhabdus spp. live in close symbiosis with nematodes of the Steinernema genus. Steinernema nematodes infect an insect larva and release their symbionts into the haemocoel of the insect. Once released into the haemocoel, the bacteria produce bioactive compounds to create a semi-exclusive environment by inhibiting the growth of bacteria, yeasts and molds. The antimicrobial compounds thus far identified are xenocoumacins, xenortides, xenorhabdins, indole derivatives, xenoamicins, bicornutin and a number of antimicrobial peptides. The latter may be linear peptides such as the bacteriocins xenocin and xenorhabdicin, rhabdopeptides and cabanillasin, or cyclic, such as PAX lipopeptides, taxlllaids, xenobactin and szentiamide. Thus far, production of antimicrobial compounds have been reported for Xenorhabdus nematophila, Xenorhabdus budapestensis, Xenorhabdus cabanillasii, Xenorhabdus kozodoii, Xenorhabdus szentirmaii, Xenorhabdus doucetiae, Xenorhabdus mauleonii, Xenorhabdus indica and Xenorhabdus bovienii. Here we describe, for the first time, PAX lipopeptides and xenocoumacin 2 produced by Xenorhabdus khoisanae. These compounds were identified using ultraperformance liquid chromatography, linked to high resolution electrospray ionisation mass spectrometry and tandem mass spectrometry.

resultsCell-free supernatants of X. khoisanae SB10 were heat stable and active against Bacillus subtilis subsp. subtilis, Escherichia coli and Candida albicans. Five lysine-rich lipopeptides from the PAX group were identified in HPLC fractions, with PAX1' and PAX7 present in the highest concentrations. Three novel PAX7 peptides with putative enoyl modifications and two linear analogues of PAX1' were also detected. A small antibiotic compound, yellow in colour and λ

conclusionWith UPLC-MS and MS

Indexed as

Anti-Infective AgentsBacillus subtilisBacterial ProteinsBenzopyransBiosynthetic PathwaysCandida albicansChromatography, High Pressure LiquidEscherichia coliLipopeptidesSpectrometry, Mass, Electrospray IonizationSymbiosisTandem Mass SpectrometryXenorhabdusAnti-Infective AgentsBacterial ProteinsBenzopyransLipopeptidesxenocoumacin 2Antimicrobial complexLys-rich PAX lipopeptidesMass spectrometric analysisXenocoumacinXenorhabdus khoisanae

Identifiers

PMID31195965
PMCPMC6567599
OpenAlexW2951623924

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.